Examination of mined junk DNA sequences has helped identify a non-protein-coding RNA whose expression is linked to ovarian cancer.
A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.
Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.
Olaparib with carboplatin and paclitaxel was found to be safe for the treatment of patients with relapsed ovarian cancer.
A drug originally used to treat ovarian cancer has shown promising results in patients with advanced peritoneal cancers during a phase I clinical trial.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|